山東羅欣藥業集團股份有限公司招標公告
October 22, 2015, Shandong Luoxin Pharmaceutical Croup Stock Co., Ltd (“Luoxin”) entered into an agreement with CJ HealthCare Corporation (“CJ HealthCare”). The agreement grants Luoxin an exclusive right to develop, manufacture and commercialize its asset CJ-12420 for the treatment of Gastrointestinal acid-related disease in the territory of mainland China.
2015年10月22日，山東羅欣藥業集團股份有限公司（“羅欣藥業”）與CJ 醫藥健康公司 (“CJ HealthCare”)在上海簽訂了合作協議，該協議授予羅欣藥業在中國開發、生產和商業化其針對胃腸道酸相關疾病的候選藥物CJ-12420的獨家權利。
上圖為羅欣藥業董事會主席劉保起先生與CJ HealthCare總裁兼首席執行官Seok-Hee Kang成功簽約并合影留念
Under the Agreement, Luoxin will be responsible for development, manufacture and commercial activities in the Territory and associated expenses. Terms of the Agreement include up-front payment, and subsequent clinical, regulatory, and performance-based milestone payments. Luoxin will also pay CJ HealthCare double-digit percentage royalties on net sales of CJ-12420 in the Territory. Luoxin and CJ HealthCare have agreed on the initial development plan that will be executed by Luoxin. It is anticipated that the clinical trial application will be submitted in the first half of 2016.
根據該協議，羅欣藥業將負責該產品在中國的開發、生產、商業化及相關費用。該協議條款包括首付款、臨床、上市及銷售里程碑款。同時，羅欣藥業也將向CJ HealthCare支付針對CJ-12420在中國凈銷售額的兩位數提成。羅欣藥業及CJ HealthCare已商定先期的開發計劃并由羅欣藥業進行執行，臨床試驗申請預計將于2016年上半年提交。
"We are pleased to partner with CJ HealthCare to develop and commercialize CJ-12420 in China," said Baoqi Liu, Chairman of the Board of Luoxin. "CJ-12420 is an excellent fit with Luoxin's commercial capabilities and portfolio, and we believe that we can move CJ-12420 development rapidly as a new treatment option to address the unmet needs of Chinese patients with Gastrointestinal acid-related diseases. Rely on the comprehensive capability of the Luoxin including development, manufacture and commercialization, we expect to bring to more innovative and clinical differentiated medicine to Chinese patients ”
羅欣藥業董事會主席劉保起先生表示：“很高興CJ HealthCare選擇與我們在中國進行CJ-12420的開發和商業化合作，該產品與羅欣藥業的商業實力和產品線非常契合，我們相信通過羅欣藥業對CJ-12420開發的快速推進，將使其成為解決中國胃腸道酸相關疾病患者的一項新的治療選擇。同時，依托羅欣藥業集團包括研發，生產及商業化的綜合實力，我們希望把更多創新的具有臨床優勢的產品帶給中國的患者?！?nbsp;
"This transaction helps us further our goal of maximizing the value of CJ-12420 by selectively licensing rights to the product outside of Korea," said Seok-Hee, Kang, CJ HealthCare's President and Chief Executive Officer. "Luoxin is a leading pharmaceutical company in China with an impressive track record of achieving development, registration and effectively commercializing pharmaceutical products, especially for the acid inhibition treatment market in China, will achieve a great success in the China market."
Seok-Hee Kang，CJ HealthCare的總裁兼首席執行官表示：“在韓國以外的地區，通過產品授權的合作方式，將進一步實現CJ-12420價值最大化的商業目標。我們相信憑借羅欣藥業的綜合研發能力，注冊管理經驗和市場優勢，特別是在中國胃腸道市場的能力，必將開發出該產品在中國市場的巨大潛力”。
CJ-12420 is a potassium-competitive acid blocker (P-CAB) in Phase 3 development for the treatment of reflux esophagitis and other acid-related GI diseases. CJ-12420 competitively inhibits the binding of potassium ions to H+,K+-ATPase in the final step of gastric acid secretion in gastric parietal cells, which has the potential to provide a strong and sustained acid secretion inhibitory effect.
CJ-12420是一種鉀離子競爭性酸抑制劑（P-CAB），目前處于臨床3期階段用于治療反流性食管炎及其他酸相關腸胃疾病。CJ-12420在胃壁細胞分泌胃酸的最后階段競爭性地阻斷鉀離子與氫離子及鉀離子-三磷酸腺苷酶的結合，可對胃酸分泌產生強大而持久的抑制效果。
Pursuant to the statistics from IMS, in mainland China, the CAGR (Compound Annual Growth Rate) of Gastrointestinal anti-acids market is about 25% in 2010-2014, and the annual sales revenue reached 2.6 billion US dollars in 2014.
根據IMS數據顯示，中國胃腸道抗酸藥市場于2010年至2014年間的復合年增長率約為25%，2014年年度銷售收入達到26億美元。
上圖為羅欣藥業CJ醫藥健康，CJ-12420簽約儀式現場
About Luoxin
關于羅欣藥業
Luoxin is a well-established domestic pharmaceutical company in China, which has the full chain capability of R&D, manufacture, supply, and commercialization. In 2014, sales revenue reached 1B USD. In 2014, Luoxin Shanghai R&D center was set up, with the commitment to enrich current pipelines (generics) with innovative medicines, through in-licensing and strategic partnerships. With the comprehensive capabilities in China market, Luoxin is committed and dedicated to provide good medicines to Chinese patients. For further information, please visit us at www.luoxinbio.com.
羅欣藥業是一家擁有完善體系的中國本土醫藥公司，具備完整的研發、生產、供應和商業化能力，在2014年銷售收入達到10億美元。2014年，羅欣藥業在上海設立研發中心，致力于通過創新藥物的引進與戰略合作，在現有仿制品藥物基礎上完善及加強其產品線。基于在中國市場的的綜合實力優勢，羅欣藥業致力于為中國患者提供優良的藥物。更多資料請訪問www.luoxinbio.com.
About CJ HealthCare
關于CJ HealthCare
CJ HealthCare Corp. is a wholly owned subsidiary of CJ CheilJedang Corp., which is the backbone of Korea's giant CJ Group. Since its establishment in 1984, CJ HealthCare has taken firm leadership in the local pharmaceutical market thanks to its product lineup of prescription drugs such as gastrointestinal, anticancer, circulatory system, diabetes, and kidney disease treatments and over-the-counter (OTC) drugs. CJ HealthCare continues its commitment to R&D and innovation for the healthier future of human beings. CJ HealthCare looks set to secure the product pipelines of new drugs and biologics based on its invaluable human resources with globally competitive R&D competencies by 2020 and globalize its arena through tapping into overseas markets more proactively. CJ HealthCare discovers, develops, manufactures and markets mainly prescription drugs and achieved 435 Million USD with 1,156 employees in 2014. For further information, please visit us at www.cjp.co.kr.
CJ HealthCare Corp.是CJ CheilJedang Corp.的全資子公司，而CJ CheilJedang Corp.為韓國巨擘CJ Group的骨干企業。自1948年成立以來，CJ HealthCare憑借其處方藥，如腸胃藥、抗癌藥、循環系統藥、糖尿病藥及腎藥，及非處方藥品組合，于韓國藥品市場獨占鰲頭。CJ HealthCare繼續致力于研發及創新，造福人類未來健康生活。CJ HealthCare務求于2020年基于其寶貴人力資源及具有全球競爭力的研發能力確保推出新藥品及生物產品系列，并透過更積極進軍海外市場，將業務拓展至全球范疇。CJ HealthCare主要物色、開發、生產及營銷處方藥，于2014年取得4.35億美元，旗下有1,156名雇員。更多資料請訪問www.cjp.co.kr.
Contract 聯系人
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.山東羅欣藥業集團股份有限公司
Peter Ji
Business Development Director業務發展總監
86(21)50860180 - 8865
or
CJ HealthCare Corporation
Seoung-Pill Shin
Strategy Support Specialist戰略支持專員
82(2) 67402154
